Navigation Links
LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
Date:6/4/2009

COPENHAGEN, June 4 /PRNewswire/ -- Santaris Pharma today announced that the cancer drug EZN-2968 - an inhibitor of HIF-1alpha, jointly developed by Enzon Pharmaceuticals and Santaris Pharma A/S - was well tolerated and showed early signs of clinical benefit in previously treated cancer patients with advanced malignancies. EZN-2968 is being evaluated in patients with solid tumors and lymphoma. The study data, which was presented at the 2009 American Society of Clinical Oncology (ASCO) annual meeting in Florida last week, demonstrated that EZN-2968 is well tolerated, and that early signs of clinical benefit - prolonged stable disease - were observed in several patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

"We have yet to see a dose limiting toxicity and we continue to be encouraged by the early clinical signals in this program," said Jeffrey H. Buchalter, Enzon's Chairman and Chief Executive Officer. "The duration of clinical benefit in certain histologies has exceeded our expectations at this phase of development. We look forward to advancing this promising compound into Phase II trials later this year, once a dose is determined."

"We are encouraged by the progress in the development of this LNA-based HIF-1 alpha inhibitor. The fact that LNA-based RNA inhibitors are beginning to show signs of clinical benefit in cancer patients is very rewarding and is further evidence of the potential of our LNA Drug Platform to generate effective and safe medicines to treat important diseases across a broad range of therapeutic areas," said S0ren Tulstrup, President & CEO of Santaris Pharma A/S.

HIF-1 alpha is a well-validated target in many common solid tumors. EZN-2968 is the first drug candidate to target the HIF-1 transcription factor, which regulates expression of many key genes i
'/>"/>

SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
2. LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs
3. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
4. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
5. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
6. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
7. AlphaVax Announces New CMV Advisory Board
8. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
9. Maxygen Announces Hold on MAXY-alpha Development Program
10. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
11. Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Last week in Alexandria, VA, the Department of Health ... Policy and Accountability (OGAPA) recognized the National Institutes of ... for a special "team" recognition award for superior efforts ... to market and "contributing to public health." The award ...
... Researchers in the Materials Science and Technology division ... electrical injection, detection and precession of spin accumulation ... technology, at temperatures up to 225 degrees Celsius. ... accumulation in Si is viable as a basis ...
... (NASDAQ: CDXS ) today announced financial results for ... First Quarter Financial Highlights:Revenue: For the first quarter of ... of 21% from $25.7 million in the first quarter of ... same time period driven by more than $5 million in ...
Cached Biology Technology:Larta Institute Receives Award for National Institutes of Health Commercialization Assistance Program at 2011 Acquisition, Grants, and Small Business Symposium 2NRL scientists achieve high temperature milestone in silicon spintronics 2NRL scientists achieve high temperature milestone in silicon spintronics 3Codexis Reports First Quarter 2011 Results 2Codexis Reports First Quarter 2011 Results 3Codexis Reports First Quarter 2011 Results 4Codexis Reports First Quarter 2011 Results 5Codexis Reports First Quarter 2011 Results 6Codexis Reports First Quarter 2011 Results 7
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... April 12, 2010 More than one third of Americans ... have a body mass index (BMI) greater than 40. The ... Association focuses on the ever-increasing use of bariatric surgery ... obesity and the important role that registered dietitians play in ...
... HEIDELBERG, Germany, 12 April 2010 More than 120 ... The EMBO Meeting 2010 the second annual life sciences ... and held in Barcelona from 4 - 7 September 2010. ... Elizabeth Blackburn Roles of telomeres & telemorase in ...
... British scientific expedition has discovered the world,s deepest undersea ... metres) deep in the Cayman Trough in the Caribbean. ... Royal Research Ship James Cook, the scientists found slender ... seafloor, erupting water hot enough to melt lead, nearly ...
Cached Biology News:Registered dietitians play essential role in management of gastric bypass patients 2Registered dietitians play essential role in management of gastric bypass patients 3Call for abstracts and registration the EMBO Meeting 2010 2Call for abstracts and registration the EMBO Meeting 2010 3British scientific expedition discovers world's deepest known undersea volcanic vents 2British scientific expedition discovers world's deepest known undersea volcanic vents 3
... is a cytidine analog that has been shown ... Immunogen: Chemical / Small Molecule conjugated ... of the ddC antiserum was determined by calculating ... moles of ddC analog at the 50% intercept ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
...
Biology Products: